neurodegeneration with brain iron accumulation

{{Short description|Group of neurodegenerative disorders with associated iron accumulation in the brain}}

{{Infobox medical condition

| name = Neurodegeneration with brain iron accumulation

| synonyms = NBIA

| image =

| alt =

| caption =

| pronounce =

| field =

| symptoms =

| complications =

| onset =

| duration =

| types =

| causes =

| risks =

| diagnosis =

| differential =

| prevention =

| treatment =

| medication =

| prognosis =

| frequency =

| deaths =

}}

Neurodegeneration with brain iron accumulation is a heterogenous group of inherited neurodegenerative diseases, still under research, in which iron accumulates in the basal ganglia, either resulting in progressive dystonia, parkinsonism, spasticity, optic atrophy, retinal degeneration, neuropsychiatric, or diverse neurologic abnormalities.{{cite book |last1=Ward |first1=Roberta J. |last2=Chrichton|first2=Robert R. |editor1-last=Sigel|editor1-first=Astrid |editor2-last=Freisinger|editor2-first=Eva |editor3-last=Sigel|editor3-first=Roland K. O. |editor4-last=Carver|editor4-first=Peggy L. |title=Essential Metals in Medicine:Therapeutic Use and Toxicity of Metal Ions in the Clinic |journal=Metal Ions in Life Sciences |volume=19 |publisher=de Gruyter GmbH|location=Berlin |isbn=978-3-11-052691-2 |pmid=30855105 |pages=87–122|chapter=Chapter 4. Ironing out the Brain |doi=10.1515/9783110527872-010 |date=2019}}

Some of the NBIA disorders have also been associated with several genes in synapse and lipid metabolism related pathways.{{cite journal |vauthors=Bettencourt C, Forabosco P, Wiethoff S, Heidari M, Johnstone DM, Botía JA, Collingwood JF, Hardy J, Milward EA, Ryten M, Houlden H |title=Gene co-expression networks shed light into diseases of brain iron accumulation |journal=Neurobiology of Disease |volume=87 |pages=59–68 |pmid=26707700 |pmc=4731015 |department=primary |doi=10.1016/j.nbd.2015.12.004 |date=March 2016}} NBIA is not one disease but an entire group of disorders, characterized by an accumulation of brain iron, sometimes in the presence of axonal spheroids in the central nervous system.{{cite journal |vauthors=Gregory A, Polster BJ, Hayflick SJ |title=Clinical and genetic delineation of neurodegeneration with brain iron accumulation |journal=Journal of Medical Genetics |volume=46 |issue=2 |pages=73–80 |pmid=18981035 |pmc=2675558 |department=review |doi=10.1136/jmg.2008.061929 |date=February 2009}}

Iron accumulation can occur anywhere in the brain, with accumulation typically occurring in globus pallidus, substantia nigra, pars reticula, striatum and cerebellar dentate nuclei. Symptoms can include various movement disorders, neuropsychiatric issues, seizures, visual disturbances, and cognitive decline, usually in different combinations. Ten to fifteen genetic NBIA disorders involving various cell processes have been identified: iron metabolism, coenzyme A biosynthesis, phospholipid metabolism, ceramide metabolism, lysosomal disorders, as well as mutations in genes with unknown functions.{{cite journal |last1=Spaull |first1=Robert V. V. |last2=Soo |first2=Audrey K. S. |last3=Hogarth |first3=Penelope |last4=Hayflick |first4=Susan J. |last5=Kurian |first5=Manju A. |title=Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation |journal=Tremor and Other Hyperkinetic Movements |volume=11 |issue=1 |pages=51 |doi-access=free |doi=10.5334/tohm.661 |date=24 November 2021|pmid=34909266 |pmc=8641530 }} Onset can occur at different ages, from early childhood to late adulthood.{{cite journal |vauthors=Dusek P, Schneider SA |title=Neurodegeneration with brain iron accumulation |journal=Current Opinion in Neurology |volume=25 |issue=4 |pages=499–506 |pmid=22691760 |department=review |doi=10.1097/wco.0b013e3283550cac |date=August 2012}}

{{as of|2021}} there were no curative treatments for any of the NBIA disorders, though several medications have been subject to clinical trial including the iron chelator deferiprone.

Variants

NBIA variant	Gene	Inheritance
class="wikitable" \|+Overview of monogenic NBIA disorders{{cite book \|title=Neurodegeneration with Brain Iron Accumulation Disorders Overview \|vauthors=Gregory A, Hayflick S \|veditors=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A \|publisher=University of Washington, Seattle \|series=GeneReviews [Internet] \|location=Seattle (WA) \|pmid=23447832 \|date=28 February 2013 \|url=https://www.ncbi.nlm.nih.gov/books/NBK121988/}}{{cite journal \|vauthors=Hogarth P \|title=Neurodegeneration with brain iron accumulation: diagnosis and management \|language=en \|journal=Journal of Movement Disorders \|volume=8 \|issue=1 \|pages=1–13 \|pmid=25614780 \|pmc=4298713 \|doi=10.14802/jmd.14034 \|date=January 2015}}
Pantothenate kinase-associated neurodegeneration (PKAN){{cite journal \|vauthors=Gregory A, Hayflick SJ \|veditors=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A \|title=Pantothenate Kinase-Associated Neurodegeneration \|journal=GeneReviews [Internet] \|year=2003 \|pmid=20301663 \|url=https://www.ncbi.nlm.nih.gov/books/NBK1490/}}	PANK2	autosomal recessive
PLA2G6-associated neurodegeneration (PLAN){{cite journal \|vauthors=Gregory A, Kurian MA, Maher ER, Hogarth P, Hayflick SJ \|veditors=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A \|title=PLA2G6-Associated Neurodegeneration \|journal=GeneReviews [Internet] \|year=2008 \|pmid=20301718 \|url=https://www.ncbi.nlm.nih.gov/books/NBK1675/}}	PLA2G6	autosomal recessive
Mitochondrial membrane protein-associated neurodegeneration (MPAN){{cite journal \|vauthors=Gregory A, Hartig M, Prokisch H, Kmiec T, Hogarth P, Hayflick SJ \|veditors=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A \|year=2014 \|title=Mitochondrial Membrane Protein-Associated Neurodegeneration \|journal=GeneReviews [Internet] \|pmid=24575447 \|url=https://www.ncbi.nlm.nih.gov/books/NBK185329/}}	C19orf12	autosomal recessive or dominant
Beta-propeller protein-associated neurodegeneration (BPAN){{cite journal \|vauthors=Gregory A, Kurian MA, Haack T, Hayflick SJ, Hogarth P \|veditors=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A \|title=Beta-Propeller Protein-Associated Neurodegeneration \|journal=GeneReviews [Internet] \|pmid=28211668 \|date=16 Feb 2017 \|url=https://www.ncbi.nlm.nih.gov/books/NBK424403/}}	WDR45	X-linked dominant (mostly de novo mutations)
Fatty acid hydroxylase-associated neurodegeneration (FAHN){{cite journal \|vauthors=Kruer MC, Gregory A, Hayflick SJ \|veditors=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A \|title=Fatty Acid Hydroxylase-Associated Neurodegeneration \|journal=GeneReviews [Internet] \|pmid=21735565 \|date=28 Jun 2011 \|url=https://www.ncbi.nlm.nih.gov/books/NBK56080/}}	FA2H	autosomal recessive
Kufor–Rakeb syndrome	ATP13A2	autosomal recessive
Neuroferritinopathy	FTL	autosomal dominant
Aceruloplasminemia	CP	autosomal recessive
Woodhouse–Sakati syndrome	DCAF17	autosomal recessive
COASY protein-associated neurodegeneration (CoPAN)	COASY	autosomal recessive
NBIA7{{cite journal \|vauthors=Drecourt A, Babdor J, Dussiot M, Petit F, Goudin N, Garfa-Traoré M, Habarou F, Bole-Feysot C, Nitschké P, Ottolenghi C, Metodiev MD, Serre V, Desguerre I, Boddaert N, Hermine O, Munnich A, Rötig A \|display-authors=6 \|title=Impaired Transferrin Receptor Palmitoylation and Recycling in Neurodegeneration with Brain Iron Accumulation \|journal=American Journal of Human Genetics \|volume=102 \|issue=2 \|pages=266–277 \|pmid=29395073 \|pmc=5985451 \|department=primary \|doi=10.1016/j.ajhg.2018.01.003 \|date=February 2018}}	REPS1	autosomal recessive
NBIA8	CRAT	autosomal recessive

Symptoms and signs

Cause

Diagnosis

DaT scans, transcranial Doppler sonography (TCD), PET scans, and, in some cases, magnetic resonance imaging (MRI) (type of scans depending on the symptoms)Brüggemann N. et al.: Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol. 2010 Nov;67(11):1357-63. doi: 10.1001/archneurol.2010.281. are used to distinguish between the different forms of NBIA due to the accumulation of iron in different areas of the brain.{{cite journal |vauthors=Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H |title=Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations |journal=American Journal of Neuroradiology |volume=27 |issue=6 |pages=1230–3 |pmid=16775270 |pmc=2099458 |department=primary |date=2006-06-01 |url=https://www.ajnr.org/content/27/6/1230}} Patients typically fall into two different categories: (1) early onset, rapid progression or (2) late onset, slow progression. The first type is considered to be the classic presentation, while the second type is thought to be a more atypical presentation. Phenotypes of the different disorders appear to be dependent on age, i.e. amount of iron accumulation and cognitive abilities.{{cite journal |vauthors=Schneider SA, Bhatia KP |title=Syndromes of neurodegeneration with brain iron accumulation |journal=Seminars in Pediatric Neurology |volume=19 |issue=2 |pages=57–66 |pmid=22704258 |department=review |doi=10.1016/j.spen.2012.03.005 |date=June 2012}}

Treatments

Effective disease-modifying treatments have not yet been found for any of the NBIA disorders. Treatment is supportive and focused on improving symptoms: Dystonia is a common debilitating symptom and can be managed with oral medications, and sometimes with deep-brain electrical stimulation, therapy support for walking, eating, and manual tasks is essential. Later, in many of the diseases, slowing and stopping of movement (known as parkinsonism) can become common. Removal of iron, using medications known as iron chelators, has been tested in clinical trial but was not definitively shown to be effective.{{cite journal |last1=Klopstock |first1=Thomas |last2=Tricta |first2=Fernando |last3=Neumayr |first3=Lynne |last4=Karin |first4=Ivan |last5=Zorzi |first5=Giovanna |last6=Fradette |first6=Caroline |last7=Kmieć |first7=Tomasz |last8=Büchner |first8=Boriana |last9=Steele |first9=Hannah E |last10=Horvath |first10=Rita |last11=Chinnery |first11=Patrick F |last12=Basu |first12=Anna |last13=Küpper |first13=Clemens |last14=Neuhofer |first14=Christiane |last15=Kálmán |first15=Bernadette |last16=Dušek |first16=Petr |last17=Yapici |first17=Zuhal |last18=Wilson |first18=Ian |last19=Zhao |first19=Feng |last20=Zibordi |first20=Federica |last21=Nardocci |first21=Nardo |last22=Aguilar |first22=Christine |last23=Hayflick |first23=Susan J |last24=Spino |first24=Michael |last25=Blamire |first25=Andrew M |last26=Hogarth |first26=Penelope |last27=Vichinsky |first27=Elliott |title=Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study |journal=The Lancet Neurology |volume=18 |issue=7 |pages=631–642 |display-authors=5 |doi=10.1016/S1474-4422(19)30142-5 |date=July 2019|pmid=31202468 |s2cid=186245765 }}

References

External links

{{Medical resources

| ICD11 =

| ICD10 = {{ICD10|G23.0}}

| ICD10CM =

| ICD9 =

| ICDO =

| OMIM =

| MeshID = C538421

| DiseasesDB = 35160

| SNOMED CT =

| Curlie =

| MedlinePlus = 001225

| eMedicineSubj =

| eMedicineTopic =

| PatientUK =

| NCI =

| GeneReviewsNBK = NBK121988

| GeneReviewsName = Neurodegeneration with Brain Iron Accumulation Disorders Overview

| NORD =

| GARDNum = 11899

| GARDName = Neurodegeneration with brain iron accumulation

| RP = neurodegeneration-with-brain-iron-accumulation

| AO =

| WO =

| OrthoInfo =

| Orphanet = 385

| Scholia =

| OB =

}}

[https://www.ninds.nih.gov/health-information/disorders/neurodegeneration-brain-iron-accumulation Neurodegeneration with Brain Iron Accumulation] information page from the National Institute of Neurological Disorders and Stroke

Category:Basal ganglia

Category:Central nervous system disorders

Category:Extrapyramidal and movement disorders

Category:Vitamin, coenzyme, and cofactor metabolism disorders